ABSTRACT
Several clinical trials suggest that botulinum toxin type-A [BTX-A] may be an effective treatment options for patients with chronic tension-type headache; however, controversy remains as how botulinum toxin optimally should be used for treating headache and which patients profile that fit for this treatment. The objective of this study was to evaluate the efficacy and tolerability of BTX-A for the prophylactic treatment of chronic tension-type headache in Egyptian patients. This was a randomized, single-blind, placebo-controlled study of botulinum toxin type-A for the treatment of patients aged 25 to 50 years old with chronic tension-type headache. Following a 30-day screening; headache parameters and severity assessed by the standard visual analogue scale [VAS] and the 25-item Henry Ford Hospital Headache Disability Inventory [HDI] were recorded as a baseline. Then, injection was done with either BTX-A or with saline by a combination of two methods for detecting injection sites [the fixed-site approach and follow-the-pain approach]. Our study showed significant improvement after one month of BTX-A injection regarding headache days/month, severity measured by VAS and HDI in headache severity. There was significant reduction of prophylactic medications, and there were minor complications but these reversed spontaneously without further treatment. BTX-A was an effective and well-tolerated prophylactic treatment in Egyptian patients with chronic tension-type headache